Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate

rVSV-Spike (rVSV-S) is a recombinant viral vaccine candidate under development to control the COVID-19 pandemic and is currently in phase II clinical trials. rVSV-S induces neutralizing antibodies and protects against SARS-CoV-2 infection in animal models. Bringing rVSV-S to clinical trials required...

Descripción completa

Detalles Bibliográficos
Autores principales: Makovitzki, Arik, Lerer, Elad, Kafri, Yaron, Adar, Yaakov, Cherry, Lilach, Lupu, Edith, Monash, Arik, Levy, Rona, Israeli, Ofir, Dor, Eyal, Epstein, Eyal, Levin, Lilach, Toister, Einat, Hefetz, Idan, Hazan, Ophir, Simon, Irit, Tal, Arnon, Girshengorn, Meni, Tzadok, Hanan, Rosen, Osnat, Oren, Ziv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531466/
https://www.ncbi.nlm.nih.gov/pubmed/34756612
http://dx.doi.org/10.1016/j.vaccine.2021.10.045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531466/
https://www.ncbi.nlm.nih.gov/pubmed/34756612
http://dx.doi.org/10.1016/j.vaccine.2021.10.045

Ejemplares similares